全体要約
2022年の世界の筋弛緩薬市場規模は300万米ドルで、2029年には400万米ドルに成長すると予測されており、2023年から2029年までの年平均成長率（CAGR）は4.7%と見込まれています。
慢性疼痛、神経障害、筋骨格障害の増加が市場成長を促進し、北米とヨーロッパが主要な市場を占めるとされています。
筋弛緩薬は筋肉の痙攣や硬直を和らげる薬で、神経インパルスをブロックすることで筋肉の収縮を抑えます。市場は中枢作用型と末梢作用型に分かれ、病院薬局、小売薬局、オンライン薬局での利用が見込まれています。
関連する質問
300万米ドル（2022年）
4.7%（2023年から2029年）
Amneal Pharmaceuticals LLC, Ipsen Biopharmaceuticals, Inc., Merz Pharmaceuticals, LLC., Par Pharmaceutical, Endo Pharmaceuticals, Vertical Pharmaceuticals, Mallinckrodt, SteriMax, Eisai, Metacel Pharmaceuticals, LLC., Teva Pharmaceuticals USA, Pfizer, Novartis AG, Johnson & Johnson, Merck & Co., Inc., Eli Lilly and Company
慢性疼痛の増加, 神経障害の増加, 筋骨格障害の増加
概要
世界の筋弛緩薬市場は、慢性的な痛み、神経障害、筋骨格障害などの状態の増加により、安定した成長が期待されています。市場は、これらの疾患の発生率が高く、これらの地域での医療技術の普及が進んでいるため、北米とヨーロッパが支配することが予想されます。
筋弛緩剤は、筋肉の痙攣やこわばりを和らげる薬です。これらの薬は、筋肉を収縮させる神経衝動をブロックすることによって作用します。
LPI (LP Information)の最新の調査報告書「筋弛緩薬産業予測」では、過去の販売状況を調査し、2022年の世界の筋弛緩薬の売上をレビューしています。また、2023年から2029年にかけての地域および市場セクター別の筋弛緩薬の売上予測に関する包括的な分析を提供。地域、市場セクター、サブセクター別に筋弛緩薬の売上が分解され、この報告書では世界の筋弛緩薬産業に関する詳細な分析が百万米ドル単位で示されています。
このインサイトレポートは、世界の筋弛緩薬市場の包括的な分析を提供し、製品セグメンテーション、企業の形成、収益、市場シェア、最新の動向、M&A活動に関連する重要なトレンドを強調しています。また、このレポートでは、筋弛緩薬のポートフォリオと能力、市場参入戦略、市場ポジション、地理的フットプリントに焦点を当て、世界の筋弛緩薬市場が加速する中で、これらの企業の独自の位置をよりよく理解するために、主要なグローバル企業の戦略を分析しています。
このインサイトレポートは、筋弛緩薬の世界的な展望を形成する主要な市場動向、要因、影響を評価し、タイプ、用途、地域、市場規模別に予測を分解して、新たな機会のポケットを強調しています。数百のボトムアップの定性的および定量的市場インプットに基づく透明性のある方法論を用いたこの研究の予測は、現在の状態と今後の軌道に関する非常に詳細な見解を提供します。
このレポートは、製品タイプ、用途、主要メーカー、および主要地域や国ごとの筋弛緩薬市場の包括的な概要、市場シェア、成長機会を示しています。
市場セグメンテーション:
タイプ別セグメンテーション
中枢作用型筋弛緩薬
末梢作用型筋弛緩薬
用途別のセグメンテーション
病院薬局
小売薬局
オンライン薬局
この報告書は、地域別に市場を分割しています。
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下にプロフィールが掲載されている企業は、一次専門家から収集された情報と、企業のカバレッジ、製品ポートフォリオ、市場浸透率を分析した結果に基づいて選定されています。
アムニール・ファーマシューティカルズLLC
Lpsenバイオファーマシューティカルズ株式会社
メルツ・ファーマシューティカルズ株式会社
パーファーマシューティカル
エンドファーマシューティカルズ
バーティカル・ファーマシューティカルズ
マリンカート
ステリマックス
エーザイ
メタセル製薬株式会社。
テバ製薬 USA
ファイザー
ノバルティスAG、
ジョンソン・エンド・ジョンソン
メルク・アンド・カンパニー、インク
イーライリリー社
本報告書での主要な質問
グローバル筋弛緩薬市場の10年先の展望は何ですか？
筋弛緩薬市場の成長を推進している要因は何ですか、世界的および地域別に。
どの技術が市場と地域ごとに最も早い成長を遂げる可能性がありますか？
筋弛緩薬の市場機会は最終市場の規模によってどのように異なりますか？
筋弛緩剤の種類、用途の内訳はどのようになりますか？
COVID-19とロシア・ウクライナ戦争の影響は何ですか？
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの筋弛緩薬、年間売上、2018年～2029年
2.1.2 筋弛緩薬の世界市場の現状分析・将来予測、地理別、2018年、2022年および2029年
2.1.3 筋弛緩薬の世界市場の現状分析・将来予測、国・地域別、2018年、2022年および2029年
2.2 筋弛緩薬セグメント、タイプ別
2.2.1 中枢性筋弛緩薬
2.2.2 末梢性筋弛緩薬
2.3 筋弛緩薬の売上、タイプ別
2.3.1 グローバルにおける筋弛緩薬の売上・市場シェア、タイプ別（2018年～2023年）
2.3.2 筋弛緩薬のグローバルレベニュー・市場シェア、タイプ別（2018～2023年）
2.3.3 グローバルの筋弛緩薬、販売価格（タイプ別）（2018年～2023年）
2.4 筋弛緩薬セグメント、用途別
2.4.1 病院薬局
2.4.2 小売薬局
2.4.3 オンラインファーマシー
2.5 筋弛緩薬の売上、用途別
2.5.1 グローバルの筋弛緩薬、収益・市場シェア（用途別）（2018年～2023年）
2.5.2 筋弛緩薬のグローバルレベニュー・市場シェア、用途別（2018～2023年）
2.5.3 グローバルの筋弛緩薬、販売価格（用途別）（2018年～2023年）
3 グローバルにおける筋弛緩薬、企業別
3.1 グローバルにおける筋弛緩薬市場のブレークダウンデータ、企業別
3.1.1 グローバルにおける筋弛緩薬の年間売上、企業別（2018年～2023年）
3.1.2 グローバルにおける筋弛緩薬の売上・市場シェア、企業別（2018年～2023年）
3.2 グローバルにおける筋弛緩薬の年間収益、企業別（2018年～2023年）
3.2.1 グローバルにおける筋弛緩薬市場の収益規模、企業別（2018年～2023年）
3.2.2 グローバルにおける筋弛緩薬市場の収益シェア、企業別（2018年～2023年）
3.3 グローバルにおける筋弛緩薬の販売価格、企業別
3.4 筋弛緩薬の主要メーカー、生産地域分布、販売地域、製品タイプ
3.4.1 筋弛緩薬の主要メーカー、製品と拠点の分布
3.4.2 プレイヤーが提供している筋弛緩薬製品
3.5 市場集中度分析
3.5.1 競合情勢分析
3.5.2 集中度レシオ（CR3、CR5、CR10）（2018年～2023年）
3.6 新製品・潜在的参入
3.7 M&A、拡大
4 筋弛緩薬の世界市場過去推移レビュー、地理別
4.1 筋弛緩薬の世界市場規模の過去推移、地理別（2018年～2023年）
4.1.1 グローバルにおける筋弛緩薬の年間売上、地理別（2018年～2023年）
4.1.2 グローバルにおける筋弛緩薬の年間収益、地理別（2018年～2023年）
4.2 筋弛緩薬の世界市場規模の過去推移、国・地域別（2018年～2023年）
4.2.1 グローバルにおける筋弛緩薬の年間売上、国・地域別（2018年～2023年）
4.2.2 グローバルにおける筋弛緩薬の年間収益、国・地域別（2018年～2023年）
4.3 アメリカズにおける筋弛緩薬の売上成長
4.4 APACにおける筋弛緩薬の売上成長
4.5 ヨーロッパにおける筋弛緩薬の売上成長
4.6 中東・アフリカにおける筋弛緩薬の売上成長
5 アメリカズ
5.1 アメリカズにおける筋弛緩薬の売上、国別
5.1.1 アメリカズにおける筋弛緩薬の売上規模、国別（2018年～2023年）
5.1.2 アメリカズにおける筋弛緩薬市場の収益規模、国別（2018年～2023年）
5.2 アメリカズにおける筋弛緩薬の売上、タイプ別
5.3 アメリカズにおける筋弛緩薬の売上、用途別
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける筋弛緩薬の売上、地域別
6.1.1 APACにおける筋弛緩薬の売上規模、地域別（2018年～2023年）
6.1.2 APACにおける筋弛緩薬市場の収益規模、地域別（2018年～2023年）
6.2 APACにおける筋弛緩薬の売上、タイプ別
6.3 APACにおける筋弛緩薬の売上、用途別
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
6.10 中国の台湾
7 ヨーロッパ
7.1 ヨーロッパにおける筋弛緩薬、国別
7.1.1 ヨーロッパにおける筋弛緩薬の売上規模、国別（2018年～2023年）
7.1.2 ヨーロッパにおける筋弛緩薬市場の収益規模、国別（2018年～2023年）
7.2 ヨーロッパにおける筋弛緩薬の売上、タイプ別
7.3 ヨーロッパにおける筋弛緩薬の売上、用途別
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカにおける筋弛緩薬、国別
8.1.1 中東・アフリカにおける筋弛緩薬の売上規模、国別（2018年～2023年）
8.1.2 中東・アフリカにおける筋弛緩薬市場の収益規模、国別（2018年～2023年）
8.2 中東・アフリカにおける筋弛緩薬の売上、タイプ別
8.3 中東・アフリカにおける筋弛緩薬の売上、用途別
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 製造コスト構造分析
10.1 原料・サプライヤー
10.2 筋弛緩薬の製造コスト構造分析
10.3 筋弛緩薬の製造プロセス分析
10.4 筋弛緩薬のインダストリーチェーン構造
11 マーケティング・流通・顧客
11.1 販売チャネル
11.1.1 直接チャネル
11.1.2 間接チャネル
11.2 筋弛緩薬の流通業者
11.3 筋弛緩薬の顧客
12 筋弛緩薬の世界市場予測レビュー、地理別
12.1 グローバルにおける筋弛緩薬の市場規模予測、地域別
12.1.1 グローバルの筋弛緩薬、市場予測（地域別）（2024年～2029年）
12.1.2 グローバルの筋弛緩薬、年間収益予測（地域別）（2024年～2029年）
12.2 アメリカズにおける予測、国別
12.3 APACにおける予測、地域別
12.4 ヨーロッパにおける予測、国別
12.5 中東・アフリカにおける予測、国別
12.6 グローバルにおける筋弛緩薬の市場予測、タイプ別
12.7 グローバルにおける筋弛緩薬の市場予測、用途別
13 キープレイヤー分析
13.1 Amneal Pharmaceuticals LLC
13.1.1 Amneal Pharmaceuticals LLC：企業情報
13.1.2 Amneal Pharmaceuticals LLC：筋弛緩薬製品ポートフォリオと特徴
13.1.3 Amneal Pharmaceuticals LLC：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.1.4 Amneal Pharmaceuticals LLC：主要事業概要
13.1.5 Amneal Pharmaceuticals LLC：直近の展開
13.2 lpsen Biopharmaceuticals,Inc
13.3 Merz Pharmaceuticals,LLC
13.4 ParPharmaceutical
13.4.1 ParPharmaceutical：企業情報
13.4.2 ParPharmaceutical：筋弛緩薬製品ポートフォリオと特徴
13.4.3 ParPharmaceutical：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.4.4 ParPharmaceutical：主要事業概要
13.4.5 ParPharmaceutical：直近の展開
13.5 Endo Pharmaceuticals
13.5.1 Endo Pharmaceuticals：企業情報
13.5.2 Endo Pharmaceuticals：筋弛緩薬製品ポートフォリオと特徴
13.5.3 Endo Pharmaceuticals：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.5.4 Endo Pharmaceuticals：主要事業概要
13.5.5 Endo Pharmaceuticals：直近の展開
13.6 Vertical Pharmaceuticals
13.6.1 Vertical Pharmaceuticals：企業情報
13.6.2 Vertical Pharmaceuticals：筋弛緩薬製品ポートフォリオと特徴
13.6.3 Vertical Pharmaceuticals：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.6.4 Vertical Pharmaceuticals：主要事業概要
13.6.5 Vertical Pharmaceuticals：直近の展開
13.7 Mallinckrodt
13.7.1 Mallinckrodt：企業情報
13.7.2 Mallinckrodt：筋弛緩薬製品ポートフォリオと特徴
13.7.3 Mallinckrodt：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.7.4 Mallinckrodt：主要事業概要
13.7.5 Mallinckrodt：直近の展開
13.8 SteriMax
13.8.1 SteriMax：企業情報
13.8.2 SteriMax：筋弛緩薬製品ポートフォリオと特徴
13.8.3 SteriMax：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.8.4 SteriMax：主要事業概要
13.8.5 SteriMax：直近の展開
13.9 Eisai
13.9.1 Eisai：企業情報
13.9.2 Eisai：筋弛緩薬製品ポートフォリオと特徴
13.9.3 Eisai：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.9.4 Eisai：主要事業概要
13.9.5 Eisai：直近の展開
13.10 MetacelPharmaceuticals, LLC
13.11 TevaPharmaceuticals USA
13.11.1 TevaPharmaceuticals USA：企業情報
13.11.2 TevaPharmaceuticals USA：筋弛緩薬製品ポートフォリオと特徴
13.11.3 TevaPharmaceuticals USA：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.11.4 TevaPharmaceuticals USA：主要事業概要
13.11.5 TevaPharmaceuticals USA：直近の展開
13.12 Pfizer
13.12.1 Pfizer：企業情報
13.12.2 Pfizer：筋弛緩薬製品ポートフォリオと特徴
13.12.3 Pfizer：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.12.4 Pfizer：主要事業概要
13.12.5 Pfizer：直近の展開
13.13 Novartis AG
13.14 Johnson & Johnson
13.14.1 Johnson & Johnson：企業情報
13.14.2 Johnson & Johnson：筋弛緩薬製品ポートフォリオと特徴
13.14.3 Johnson & Johnson：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.14.4 Johnson & Johnson：主要事業概要
13.14.5 Johnson & Johnson：直近の展開
13.15 Merck & Co\., Inc
13.16 Eli Lilly and Company
13.16.1 Eli Lilly and Company：企業情報
13.16.2 Eli Lilly and Company：筋弛緩薬製品ポートフォリオと特徴
13.16.3 Eli Lilly and Company：筋弛緩薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.16.4 Eli Lilly and Company：主要事業概要
13.16.5 Eli Lilly and Company：直近の展開
14 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The global muscle relaxant drugs market is expected to grow at a steady rate owing to the increasing prevalence of conditions such as chronic pain, neurological disorders, and musculoskeletal disorders. The market is expected to be dominated by North America and Europe owing to the high incidence of these diseases and the widespread adoption of healthcare technologies in these regions.
A muscle relaxant is a medication that relieves muscle spasms or stiffness. These drugs work by blocking nerve impulses that cause muscles to contract.
LPI (LP Information)' newest research report, the “Muscle Relaxant Drug Industry Forecast” looks at past sales and reviews total world Muscle Relaxant Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Muscle Relaxant Drug sales for 2023 through 2029. With Muscle Relaxant Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Muscle Relaxant Drug industry.
This Insight Report provides a comprehensive analysis of the global Muscle Relaxant Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Muscle Relaxant Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Muscle Relaxant Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Muscle Relaxant Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Muscle Relaxant Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Muscle Relaxant Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Centrally Acting Muscle Relaxants
Peripherally Acting Muscle Relaxants
Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amneal Pharmaceuticals LLC
lpsen Biopharmaceuticals,Inc.
Merz Pharmaceuticals,LLC.
ParPharmaceutical
Endo Pharmaceuticals
Vertical Pharmaceuticals
Mallinckrodt
SteriMax
Eisai
MetacelPharmaceuticals, LLC.
TevaPharmaceuticals USA
Pfizer
Novartis AG,
Johnson & Johnson
Merck & Co., Inc.
Eli Lilly and Company
Key Questions Addressed in this Report
What is the 10-year outlook for the global Muscle Relaxant Drug market?
What factors are driving Muscle Relaxant Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Muscle Relaxant Drug market opportunities vary by end market size?
How does Muscle Relaxant Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Muscle Relaxant Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Muscle Relaxant Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Muscle Relaxant Drug by Country/Region, 2018, 2022 & 2029
2.2 Muscle Relaxant Drug Segment by Type
2.2.1 Centrally Acting Muscle Relaxants
2.2.2 Peripherally Acting Muscle Relaxants
2.3 Muscle Relaxant Drug Sales by Type
2.3.1 Global Muscle Relaxant Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Muscle Relaxant Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Muscle Relaxant Drug Sale Price by Type (2018-2023)
2.4 Muscle Relaxant Drug Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Muscle Relaxant Drug Sales by Application
2.5.1 Global Muscle Relaxant Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Muscle Relaxant Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Muscle Relaxant Drug Sale Price by Application (2018-2023)
3 Global Muscle Relaxant Drug by Company
3.1 Global Muscle Relaxant Drug Breakdown Data by Company
3.1.1 Global Muscle Relaxant Drug Annual Sales by Company (2018-2023)
3.1.2 Global Muscle Relaxant Drug Sales Market Share by Company (2018-2023)
3.2 Global Muscle Relaxant Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Muscle Relaxant Drug Revenue by Company (2018-2023)
3.2.2 Global Muscle Relaxant Drug Revenue Market Share by Company (2018-2023)
3.3 Global Muscle Relaxant Drug Sale Price by Company
3.4 Key Manufacturers Muscle Relaxant Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Muscle Relaxant Drug Product Location Distribution
3.4.2 Players Muscle Relaxant Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Muscle Relaxant Drug by Geographic Region
4.1 World Historic Muscle Relaxant Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Muscle Relaxant Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Muscle Relaxant Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Muscle Relaxant Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Muscle Relaxant Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Muscle Relaxant Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Muscle Relaxant Drug Sales Growth
4.4 APAC Muscle Relaxant Drug Sales Growth
4.5 Europe Muscle Relaxant Drug Sales Growth
4.6 Middle East & Africa Muscle Relaxant Drug Sales Growth
5 Americas
5.1 Americas Muscle Relaxant Drug Sales by Country
5.1.1 Americas Muscle Relaxant Drug Sales by Country (2018-2023)
5.1.2 Americas Muscle Relaxant Drug Revenue by Country (2018-2023)
5.2 Americas Muscle Relaxant Drug Sales by Type
5.3 Americas Muscle Relaxant Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Muscle Relaxant Drug Sales by Region
6.1.1 APAC Muscle Relaxant Drug Sales by Region (2018-2023)
6.1.2 APAC Muscle Relaxant Drug Revenue by Region (2018-2023)
6.2 APAC Muscle Relaxant Drug Sales by Type
6.3 APAC Muscle Relaxant Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Muscle Relaxant Drug by Country
7.1.1 Europe Muscle Relaxant Drug Sales by Country (2018-2023)
7.1.2 Europe Muscle Relaxant Drug Revenue by Country (2018-2023)
7.2 Europe Muscle Relaxant Drug Sales by Type
7.3 Europe Muscle Relaxant Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Muscle Relaxant Drug by Country
8.1.1 Middle East & Africa Muscle Relaxant Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Muscle Relaxant Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Muscle Relaxant Drug Sales by Type
8.3 Middle East & Africa Muscle Relaxant Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Muscle Relaxant Drug
10.3 Manufacturing Process Analysis of Muscle Relaxant Drug
10.4 Industry Chain Structure of Muscle Relaxant Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Muscle Relaxant Drug Distributors
11.3 Muscle Relaxant Drug Customer
12 World Forecast Review for Muscle Relaxant Drug by Geographic Region
12.1 Global Muscle Relaxant Drug Market Size Forecast by Region
12.1.1 Global Muscle Relaxant Drug Forecast by Region (2024-2029)
12.1.2 Global Muscle Relaxant Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Muscle Relaxant Drug Forecast by Type
12.7 Global Muscle Relaxant Drug Forecast by Application
13 Key Players Analysis
13.1 Amneal Pharmaceuticals LLC
13.1.1 Amneal Pharmaceuticals LLC Company Information
13.1.2 Amneal Pharmaceuticals LLC Muscle Relaxant Drug Product Portfolios and Specifications
13.1.3 Amneal Pharmaceuticals LLC Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Amneal Pharmaceuticals LLC Main Business Overview
13.1.5 Amneal Pharmaceuticals LLC Latest Developments
13.2 lpsen Biopharmaceuticals,Inc.
13.2.1 lpsen Biopharmaceuticals,Inc. Company Information
13.2.2 lpsen Biopharmaceuticals,Inc. Muscle Relaxant Drug Product Portfolios and Specifications
13.2.3 lpsen Biopharmaceuticals,Inc. Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 lpsen Biopharmaceuticals,Inc. Main Business Overview
13.2.5 lpsen Biopharmaceuticals,Inc. Latest Developments
13.3 Merz Pharmaceuticals,LLC.
13.3.1 Merz Pharmaceuticals,LLC. Company Information
13.3.2 Merz Pharmaceuticals,LLC. Muscle Relaxant Drug Product Portfolios and Specifications
13.3.3 Merz Pharmaceuticals,LLC. Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Merz Pharmaceuticals,LLC. Main Business Overview
13.3.5 Merz Pharmaceuticals,LLC. Latest Developments
13.4 ParPharmaceutical
13.4.1 ParPharmaceutical Company Information
13.4.2 ParPharmaceutical Muscle Relaxant Drug Product Portfolios and Specifications
13.4.3 ParPharmaceutical Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 ParPharmaceutical Main Business Overview
13.4.5 ParPharmaceutical Latest Developments
13.5 Endo Pharmaceuticals
13.5.1 Endo Pharmaceuticals Company Information
13.5.2 Endo Pharmaceuticals Muscle Relaxant Drug Product Portfolios and Specifications
13.5.3 Endo Pharmaceuticals Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Endo Pharmaceuticals Main Business Overview
13.5.5 Endo Pharmaceuticals Latest Developments
13.6 Vertical Pharmaceuticals
13.6.1 Vertical Pharmaceuticals Company Information
13.6.2 Vertical Pharmaceuticals Muscle Relaxant Drug Product Portfolios and Specifications
13.6.3 Vertical Pharmaceuticals Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Vertical Pharmaceuticals Main Business Overview
13.6.5 Vertical Pharmaceuticals Latest Developments
13.7 Mallinckrodt
13.7.1 Mallinckrodt Company Information
13.7.2 Mallinckrodt Muscle Relaxant Drug Product Portfolios and Specifications
13.7.3 Mallinckrodt Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Mallinckrodt Main Business Overview
13.7.5 Mallinckrodt Latest Developments
13.8 SteriMax
13.8.1 SteriMax Company Information
13.8.2 SteriMax Muscle Relaxant Drug Product Portfolios and Specifications
13.8.3 SteriMax Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 SteriMax Main Business Overview
13.8.5 SteriMax Latest Developments
13.9 Eisai
13.9.1 Eisai Company Information
13.9.2 Eisai Muscle Relaxant Drug Product Portfolios and Specifications
13.9.3 Eisai Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Eisai Main Business Overview
13.9.5 Eisai Latest Developments
13.10 MetacelPharmaceuticals, LLC.
13.10.1 MetacelPharmaceuticals, LLC. Company Information
13.10.2 MetacelPharmaceuticals, LLC. Muscle Relaxant Drug Product Portfolios and Specifications
13.10.3 MetacelPharmaceuticals, LLC. Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 MetacelPharmaceuticals, LLC. Main Business Overview
13.10.5 MetacelPharmaceuticals, LLC. Latest Developments
13.11 TevaPharmaceuticals USA
13.11.1 TevaPharmaceuticals USA Company Information
13.11.2 TevaPharmaceuticals USA Muscle Relaxant Drug Product Portfolios and Specifications
13.11.3 TevaPharmaceuticals USA Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 TevaPharmaceuticals USA Main Business Overview
13.11.5 TevaPharmaceuticals USA Latest Developments
13.12 Pfizer
13.12.1 Pfizer Company Information
13.12.2 Pfizer Muscle Relaxant Drug Product Portfolios and Specifications
13.12.3 Pfizer Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Pfizer Main Business Overview
13.12.5 Pfizer Latest Developments
13.13 Novartis AG,
13.13.1 Novartis AG, Company Information
13.13.2 Novartis AG, Muscle Relaxant Drug Product Portfolios and Specifications
13.13.3 Novartis AG, Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Novartis AG, Main Business Overview
13.13.5 Novartis AG, Latest Developments
13.14 Johnson & Johnson
13.14.1 Johnson & Johnson Company Information
13.14.2 Johnson & Johnson Muscle Relaxant Drug Product Portfolios and Specifications
13.14.3 Johnson & Johnson Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Johnson & Johnson Main Business Overview
13.14.5 Johnson & Johnson Latest Developments
13.15 Merck & Co., Inc.
13.15.1 Merck & Co., Inc. Company Information
13.15.2 Merck & Co., Inc. Muscle Relaxant Drug Product Portfolios and Specifications
13.15.3 Merck & Co., Inc. Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Merck & Co., Inc. Main Business Overview
13.15.5 Merck & Co., Inc. Latest Developments
13.16 Eli Lilly and Company
13.16.1 Eli Lilly and Company Company Information
13.16.2 Eli Lilly and Company Muscle Relaxant Drug Product Portfolios and Specifications
13.16.3 Eli Lilly and Company Muscle Relaxant Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Eli Lilly and Company Main Business Overview
13.16.5 Eli Lilly and Company Latest Developments
14 Research Findings and Conclusion
List of Tables Table 1. Muscle Relaxant Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions) Table 2. Muscle Relaxant Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions) Table 3. Major Players of Centrally Acting Muscle Relaxants Table 4. Major Players of Peripherally Acting Muscle Relaxants Table 5. Global Muscle Relaxant Drug Sales by Type (2018-2023) & (K Units) Table 6. Global Muscle Relaxant Drug Sales Market Share by Type (2018-2023) Table 7. Global Muscle Relaxant Drug Revenue by Type (2018-2023) & ($ million) Table 8. Global Muscle Relaxant Drug Revenue Market Share by Type (2018-2023) Table 9. Global Muscle Relaxant Drug Sale Price by Type (2018-2023) & (US$/Unit) Table 10. Global Muscle Relaxant Drug Sales by Application (2018-2023) & (K Units) Table 11. Global Muscle Relaxant Drug Sales Market Share by Application (2018-2023) Table 12. Global Muscle Relaxant Drug Revenue by Application (2018-2023) Table 13. Global Muscle Relaxant Drug Revenue Market Share by Application (2018-2023) Table 14. Global Muscle Relaxant Drug Sale Price by Application (2018-2023) & (US$/Unit) Table 15. Global Muscle Relaxant Drug Sales by Company (2018-2023) & (K Units) Table 16. Global Muscle Relaxant Drug Sales Market Share by Company (2018-2023) Table 17. Global Muscle Relaxant Drug Revenue by Company (2018-2023) ($ Millions) Table 18. Global Muscle Relaxant Drug Revenue Market Share by Company (2018-2023) Table 19. Global Muscle Relaxant Drug Sale Price by Company (2018-2023) & (US$/Unit) Table 20. Key Manufacturers Muscle Relaxant Drug Producing Area Distribution and Sales Area Table 21. Players Muscle Relaxant Drug Products Offered Table 22. Muscle Relaxant Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) Table 23. New Products and Potential Entrants Table 24. Mergers & Acquisitions, Expansion Table 25. Global Muscle Relaxant Drug Sales by Geographic Region (2018-2023) & (K Units) Table 26. Global Muscle Relaxant Drug Sales Market Share Geographic Region (2018-2023) Table 27. Global Muscle Relaxant Drug Revenue by Geographic Region (2018-2023) & ($ millions) Table 28. Global Muscle Relaxant Drug Revenue Market Share by Geographic Region (2018-2023) Table 29. Global Muscle Relaxant Drug Sales by Country/Region (2018-2023) & (K Units) Table 30. Global Muscle Relaxant Drug Sales Market Share by Country/Region (2018-2023) Table 31. Global Muscle Relaxant Drug Revenue by Country/Region (2018-2023) & ($ millions) Table 32. Global Muscle Relaxant Drug Revenue Market Share by Country/Region (2018-2023) Table 33. Americas Muscle Relaxant Drug Sales by Country (2018-2023) & (K Units) Table 34. Americas Muscle Relaxant Drug Sales Market Share by Country (2018-2023) Table 35. Americas Muscle Relaxant Drug Revenue by Country (2018-2023) & ($ Millions) Table 36. Americas Muscle Relaxant Drug Revenue Market Share by Country (2018-2023) Table 37. Americas Muscle Relaxant Drug Sales by Type (2018-2023) & (K Units) Table 38. Americas Muscle Relaxant Drug Sales by Application (2018-2023) & (K Units) Table 39. APAC Muscle Relaxant Drug Sales by Region (2018-2023) & (K Units) Table 40. APAC Muscle Relaxant Drug Sales Market Share by Region (2018-2023) Table 41. APAC Muscle Relaxant Drug Revenue by Region (2018-2023) & ($ Millions) Table 42. APAC Muscle Relaxant Drug Revenue Market Share by Region (2018-2023) Table 43. APAC Muscle Relaxant Drug Sales by Type (2018-2023) & (K Units) Table 44. APAC Muscle Relaxant Drug Sales by Application (2018-2023) & (K Units) Table 45. Europe Muscle Relaxant Drug Sales by Country (2018-2023) & (K Units) Table 46. Europe Muscle Relaxant Drug Sales Market Share by Country (2018-2023) Table 47. Europe Muscle Relaxant Drug Revenue by Country (2018-2023) & ($ Millions) Table 48. Europe Muscle Relaxant Drug Revenue Market Share by Country (2018-2023) Table 49. Europe Muscle Relaxant Drug Sales by Type (2018-2023) & (K Units) Table 50. Europe Muscle Relaxant Drug Sales by Application (2018-2023) & (K Units) Table 51. Middle East & Africa Muscle Relaxant Drug Sales by Country (2018-2023) & (K Units) Table 52. Middle East & Africa Muscle Relaxant Drug Sales Market Share by Country (2018-2023) Table 53. Middle East & Africa Muscle Relaxant Drug Revenue by Country (2018-2023) & ($ Millions) Table 54. Middle East & Africa Muscle Relaxant Drug Revenue Market Share by Country (2018-2023) Table 55. Middle East & Africa Muscle Relaxant Drug Sales by Type (2018-2023) & (K Units) Table 56. Middle East & Africa Muscle Relaxant Drug Sales by Application (2018-2023) & (K Units) Table 57. Key Market Drivers & Growth Opportunities of Muscle Relaxant Drug Table 58. Key Market Challenges & Risks of Muscle Relaxant Drug Table 59. Key Industry Trends of Muscle Relaxant Drug Table 60. Muscle Relaxant Drug Raw Material Table 61. Key Suppliers of Raw Materials Table 62. Muscle Relaxant Drug Distributors List Table 63. Muscle Relaxant Drug Customer List Table 64. Global Muscle Relaxant Drug Sales Forecast by Region (2024-2029) & (K Units) Table 65. Global Muscle Relaxant Drug Revenue Forecast by Region (2024-2029) & ($ millions) Table 66. Americas Muscle Relaxant Drug Sales Forecast by Country (2024-2029) & (K Units) Table 67. Americas Muscle Relaxant Drug Revenue Forecast by Country (2024-2029) & ($ millions) Table 68. APAC Muscle Relaxant Drug Sales Forecast by Region (2024-2029) & (K Units) Table 69. APAC Muscle Relaxant Drug Revenue Forecast by Region (2024-2029) & ($ millions) Table 70. Europe Muscle Relaxant Drug Sales Forecast by Country (2024-2029) & (K Units) Table 71. Europe Muscle Relaxant Drug Revenue Forecast by Country (2024-2029) & ($ millions) Table 72. Middle East & Africa Muscle Relaxant Drug Sales Forecast by Country (2024-2029) & (K Units) Table 73. Middle East & Africa Muscle Relaxant Drug Revenue Forecast by Country (2024-2029) & ($ millions) Table 74. Global Muscle Relaxant Drug Sales Forecast by Type (2024-2029) & (K Units) Table 75. Global Muscle Relaxant Drug Revenue Forecast by Type (2024-2029) & ($ Millions) Table 76. Global Muscle Relaxant Drug Sales Forecast by Application (2024-2029) & (K Units) Table 77. Global Muscle Relaxant Drug Revenue Forecast by Application (2024-2029) & ($ Millions) Table 78. Amneal Pharmaceuticals LLC Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 79. Amneal Pharmaceuticals LLC Muscle Relaxant Drug Product Portfolios and Specifications Table 80. Amneal Pharmaceuticals LLC Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 81. Amneal Pharmaceuticals LLC Main Business Table 82. Amneal Pharmaceuticals LLC Latest Developments Table 83. lpsen Biopharmaceuticals,Inc. Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 84. lpsen Biopharmaceuticals,Inc. Muscle Relaxant Drug Product Portfolios and Specifications Table 85. lpsen Biopharmaceuticals,Inc. Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 86. lpsen Biopharmaceuticals,Inc. Main Business Table 87. lpsen Biopharmaceuticals,Inc. Latest Developments Table 88. Merz Pharmaceuticals,LLC. Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 89. Merz Pharmaceuticals,LLC. Muscle Relaxant Drug Product Portfolios and Specifications Table 90. Merz Pharmaceuticals,LLC. Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 91. Merz Pharmaceuticals,LLC. Main Business Table 92. Merz Pharmaceuticals,LLC. Latest Developments Table 93. ParPharmaceutical Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 94. ParPharmaceutical Muscle Relaxant Drug Product Portfolios and Specifications Table 95. ParPharmaceutical Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 96. ParPharmaceutical Main Business Table 97. ParPharmaceutical Latest Developments Table 98. Endo Pharmaceuticals Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 99. Endo Pharmaceuticals Muscle Relaxant Drug Product Portfolios and Specifications Table 100. Endo Pharmaceuticals Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 101. Endo Pharmaceuticals Main Business Table 102. Endo Pharmaceuticals Latest Developments Table 103. Vertical Pharmaceuticals Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 104. Vertical Pharmaceuticals Muscle Relaxant Drug Product Portfolios and Specifications Table 105. Vertical Pharmaceuticals Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 106. Vertical Pharmaceuticals Main Business Table 107. Vertical Pharmaceuticals Latest Developments Table 108. Mallinckrodt Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 109. Mallinckrodt Muscle Relaxant Drug Product Portfolios and Specifications Table 110. Mallinckrodt Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 111. Mallinckrodt Main Business Table 112. Mallinckrodt Latest Developments Table 113. SteriMax Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 114. SteriMax Muscle Relaxant Drug Product Portfolios and Specifications Table 115. SteriMax Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 116. SteriMax Main Business Table 117. SteriMax Latest Developments Table 118. Eisai Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 119. Eisai Muscle Relaxant Drug Product Portfolios and Specifications Table 120. Eisai Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 121. Eisai Main Business Table 122. Eisai Latest Developments Table 123. MetacelPharmaceuticals, LLC. Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 124. MetacelPharmaceuticals, LLC. Muscle Relaxant Drug Product Portfolios and Specifications Table 125. MetacelPharmaceuticals, LLC. Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 126. MetacelPharmaceuticals, LLC. Main Business Table 127. MetacelPharmaceuticals, LLC. Latest Developments Table 128. TevaPharmaceuticals USA Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 129. TevaPharmaceuticals USA Muscle Relaxant Drug Product Portfolios and Specifications Table 130. TevaPharmaceuticals USA Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 131. TevaPharmaceuticals USA Main Business Table 132. TevaPharmaceuticals USA Latest Developments Table 133. Pfizer Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 134. Pfizer Muscle Relaxant Drug Product Portfolios and Specifications Table 135. Pfizer Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 136. Pfizer Main Business Table 137. Pfizer Latest Developments Table 138. Novartis AG, Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 139. Novartis AG, Muscle Relaxant Drug Product Portfolios and Specifications Table 140. Novartis AG, Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 141. Novartis AG, Main Business Table 142. Novartis AG, Latest Developments Table 143. Johnson & Johnson Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 144. Johnson & Johnson Muscle Relaxant Drug Product Portfolios and Specifications Table 145. Johnson & Johnson Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 146. Johnson & Johnson Main Business Table 147. Johnson & Johnson Latest Developments Table 148. Merck & Co., Inc. Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 149. Merck & Co., Inc. Muscle Relaxant Drug Product Portfolios and Specifications Table 150. Merck & Co., Inc. Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 151. Merck & Co., Inc. Main Business Table 152. Merck & Co., Inc. Latest Developments Table 153. Eli Lilly and Company Basic Information, Muscle Relaxant Drug Manufacturing Base, Sales Area and Its Competitors Table 154. Eli Lilly and Company Muscle Relaxant Drug Product Portfolios and Specifications Table 155. Eli Lilly and Company Muscle Relaxant Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023) Table 156. Eli Lilly and Company Main Business Table 157. Eli Lilly and Company Latest Developments List of Figures Figure 1. Picture of Muscle Relaxant Drug Figure 2. Muscle Relaxant Drug Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Muscle Relaxant Drug Sales Growth Rate 2018-2029 (K Units) Figure 7. Global Muscle Relaxant Drug Revenue Growth Rate 2018-2029 ($ Millions) Figure 8. Muscle Relaxant Drug Sales by Region (2018, 2022 & 2029) & ($ Millions) Figure 9. Product Picture of Centrally Acting Muscle Relaxants Figure 10. Product Picture of Peripherally Acting Muscle Relaxants Figure 11. Global Muscle Relaxant Drug Sales Market Share by Type in 2022 Figure 12. Global Muscle Relaxant Drug Revenue Market Share by Type (2018-2023) Figure 13. Muscle Relaxant Drug Consumed in Hospital Pharmacy Figure 14. Global Muscle Relaxant Drug Market: Hospital Pharmacy (2018-2023) & (K Units) Figure 15. Muscle Relaxant Drug Consumed in Retail Pharmacy Figure 16. Global Muscle Relaxant Drug Market: Retail Pharmacy (2018-2023) & (K Units) Figure 17. Muscle Relaxant Drug Consumed in Online Pharmacy Figure 18. Global Muscle Relaxant Drug Market: Online Pharmacy (2018-2023) & (K Units) Figure 19. Global Muscle Relaxant Drug Sales Market Share by Application (2022) Figure 20. Global Muscle Relaxant Drug Revenue Market Share by Application in 2022 Figure 21. Muscle Relaxant Drug Sales Market by Company in 2022 (K Units) Figure 22. Global Muscle Relaxant Drug Sales Market Share by Company in 2022 Figure 23. Muscle Relaxant Drug Revenue Market by Company in 2022 ($ Million) Figure 24. Global Muscle Relaxant Drug Revenue Market Share by Company in 2022 Figure 25. Global Muscle Relaxant Drug Sales Market Share by Geographic Region (2018-2023) Figure 26. Global Muscle Relaxant Drug Revenue Market Share by Geographic Region in 2022 Figure 27. Americas Muscle Relaxant Drug Sales 2018-2023 (K Units) Figure 28. Americas Muscle Relaxant Drug Revenue 2018-2023 ($ Millions) Figure 29. APAC Muscle Relaxant Drug Sales 2018-2023 (K Units) Figure 30. APAC Muscle Relaxant Drug Revenue 2018-2023 ($ Millions) Figure 31. Europe Muscle Relaxant Drug Sales 2018-2023 (K Units) Figure 32. Europe Muscle Relaxant Drug Revenue 2018-2023 ($ Millions) Figure 33. Middle East & Africa Muscle Relaxant Drug Sales 2018-2023 (K Units) Figure 34. Middle East & Africa Muscle Relaxant Drug Revenue 2018-2023 ($ Millions) Figure 35. Americas Muscle Relaxant Drug Sales Market Share by Country in 2022 Figure 36. Americas Muscle Relaxant Drug Revenue Market Share by Country in 2022 Figure 37. Americas Muscle Relaxant Drug Sales Market Share by Type (2018-2023) Figure 38. Americas Muscle Relaxant Drug Sales Market Share by Application (2018-2023) Figure 39. United States Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 40. Canada Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 41. Mexico Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 42. Brazil Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 43. APAC Muscle Relaxant Drug Sales Market Share by Region in 2022 Figure 44. APAC Muscle Relaxant Drug Revenue Market Share by Regions in 2022 Figure 45. APAC Muscle Relaxant Drug Sales Market Share by Type (2018-2023) Figure 46. APAC Muscle Relaxant Drug Sales Market Share by Application (2018-2023) Figure 47. China Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 48. Japan Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 49. South Korea Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 50. Southeast Asia Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 51. India Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 52. Australia Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 53. China Taiwan Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 54. Europe Muscle Relaxant Drug Sales Market Share by Country in 2022 Figure 55. Europe Muscle Relaxant Drug Revenue Market Share by Country in 2022 Figure 56. Europe Muscle Relaxant Drug Sales Market Share by Type (2018-2023) Figure 57. Europe Muscle Relaxant Drug Sales Market Share by Application (2018-2023) Figure 58. Germany Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 59. France Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 60. UK Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 61. Italy Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 62. Russia Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 63. Middle East & Africa Muscle Relaxant Drug Sales Market Share by Country in 2022 Figure 64. Middle East & Africa Muscle Relaxant Drug Revenue Market Share by Country in 2022 Figure 65. Middle East & Africa Muscle Relaxant Drug Sales Market Share by Type (2018-2023) Figure 66. Middle East & Africa Muscle Relaxant Drug Sales Market Share by Application (2018-2023) Figure 67. Egypt Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 68. South Africa Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 69. Israel Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 70. Turkey Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 71. GCC Country Muscle Relaxant Drug Revenue Growth 2018-2023 ($ Millions) Figure 72. Manufacturing Cost Structure Analysis of Muscle Relaxant Drug in 2022 Figure 73. Manufacturing Process Analysis of Muscle Relaxant Drug Figure 74. Industry Chain Structure of Muscle Relaxant Drug Figure 75. Channels of Distribution Figure 76. Global Muscle Relaxant Drug Sales Market Forecast by Region (2024-2029) Figure 77. Global Muscle Relaxant Drug Revenue Market Share Forecast by Region (2024-2029) Figure 78. Global Muscle Relaxant Drug Sales Market Share Forecast by Type (2024-2029) Figure 79. Global Muscle Relaxant Drug Revenue Market Share Forecast by Type (2024-2029) Figure 80. Global Muscle Relaxant Drug Sales Market Share Forecast by Application (2024-2029) Figure 81. Global Muscle Relaxant Drug Revenue Market Share Forecast by Application (2024-2029)
